Clinical Trials Logo

Clinical Trial Summary

the Investigator will test the hypothesis that short term PDE5A inhibition (with tadalafil) will reduce post-exercise edema by MRI in males with Becker Muscular Dystrophy.


Clinical Trial Description

Becker muscular dystrophy (BMD) is a rare, progressive and fatal muscle disease. Tadalafil is approved by the FDA for the treatment of erectile dysfunction and pulmonary hypertension. This class of medication improves muscle blood flow in a mouse model of muscular dystrophy, prevents post-exercise muscle edema, and alleviates post-exercise muscle fatigue. To begin to translate this work from the mouse into actual patients with muscular dystrophy, the Investigator group recently demonstrated that a single dose of tadalafil can improve blood flow regulation in boys with Duchenne muscular dystrophy and men with BMD. the Investigator now wish to test the hypothesis that acute treatment with Tadalafil can prevent post-exercise muscle edema in men with BMD.

the Investigator will recruit men with BMD, and healthy age-matched controls, ages 15-55y who are ambulatory and without heart failure.

Visit 1: Participants will undergo informed consent, physical exam and medical history screening, electrocardiogram, blood pressure monitoring, blood chemistry testing, echocardiogram (ejection fraction measurement), and evaluation of skeletal muscle blood flow. Patients, but not controls, will also undergo a muscle biopsy.

Visit 2 - 4: Participants will undergo baseline magnetic resonance imaging of the forearm muscle, followed by rhythmic forearm muscle exercise (handgrip). MRI will then be repeated 2-, 4-, 24-, and 48 hours following the rhythmic handgrip exercise.

Patients with BMD will then be randomized in a 3:1 fashion to tadalafil vs. placebo.

Visit 5-7: Using a standard double-blind cross-over design, patients will be treated with either tadalafil or placebo. Magnetic resonance imaging of the forearm muscle will be performed to establish baseline measurements. Patients will then repeat the rhythmic handgrip exercise protocol performed on Visit 2, followed by MRI 2-, 4-, 24-, and 48 hours following exercise. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03076814
Study type Interventional
Source Cedars-Sinai Medical Center
Contact
Status Withdrawn
Phase N/A
Start date March 2012
Completion date December 2015

See also
  Status Clinical Trial Phase
Terminated NCT01168908 - Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Phase 2
Recruiting NCT01484678 - Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Completed NCT02847975 - Sodium Nitrate to Improve Blood Flow Phase 1
Completed NCT02147639 - Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy Phase 2/Phase 3
Recruiting NCT02069756 - The Duchenne Registry
Completed NCT04585464 - A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults Phase 1
Recruiting NCT04668716 - Brain Involvement in Dystrophinopathies Part 2
Completed NCT03236662 - (-)- Epicatechin Becker Muscular Dystrophy Phase 2
Completed NCT01350154 - Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients Phase 2
Enrolling by invitation NCT06066580 - Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy Phase 2
Not yet recruiting NCT06363526 - Effectiveness of 5-week Digital Respiratory Practice in a Group of Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy. N/A
Recruiting NCT05409079 - Schulze Muscular Dystrophy Ability Clinical Study N/A
Completed NCT01856868 - Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study) Phase 1/Phase 2
Completed NCT01557400 - Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada Phase 3
Recruiting NCT02109692 - Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies N/A
Recruiting NCT03057002 - UTSW HP [13-C] Pyruvate Injection in HCM
Recruiting NCT04583917 - Brain Involvement in Dystrophinopathies Part 1
Completed NCT02207283 - PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy Phase 4
Completed NCT00873782 - Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy Phase 1
Not yet recruiting NCT05715957 - Follow-up Study on Female Carriers With DMD Gene Variants